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Palliative Resection of Pancreatic
Adenocarclnoma
A Survey ofBritish Surgeons
C. D.JOHNSON
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A survey was carried out by postal questionnaire ofthe attitudes ofBritish surgeons to pancreatic
resection as palliation for ductal adenocarcinoma ofthe pancreas. Replies from 24 surgeons related to
experience in over 700 resections. The incidence ofestimated residual local disease after resection was
median 12.5 percent, range 0-35 percent. Half(12) ofthe surgeons felt that pancreatic resection with
residual macroscopic disease wasjustified. Only 3 (12.5 percent) surgeons accepted that palliative
resection in the presence ofliver metastases was sometimesjustifiable. Further evidence is required of
improved quality oflife after resection before the majority ofsurgeons will accept palliative resection
in the management ofpancreatic ductal adenocarcinoma.
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Resection ofpancreatic cancer, even for attempted cure,
is rarely successful. Almost always, the patient dies of
recurrent disease, butmay well have extended survival as a
result ofthe operation. Historically, the mortality ofresec-
tion was so high that palliative resection, in the presence of
irresectable local invasion or distant metastaseswas never
attempted. However since 1980 it has become clear that
pancreatic resection can be performed with mortality well
under 10%. Many surgeons can achieve operative
mortality less than 5%. In 28 reports, containing over 2,000
patients, the overall operative mortality was 6.9% 1,2 The
median (interquartile range) mortality reported by each
author was 7.5 (4.5-12) percent. If, as some surgeons
believe, resection offers the best form ofpalliation3, then
these impressively low mortality figures lead us to consider
the possibility ofpalliative resection even in the presence
ofirresectable local disease or distant metastases.
This paper reports a study ofcurrent attitudes amongst
British surgeons to palliative resection for pancreatic
carcinoma.
METHOD
A questionnaire was sent to 30 British surgeons known to
the author to have an interest in biliary and pancreatic
disease; 24 replies were received. No reminder was sent.
The questions are shown in Table 1.
The responses were tabulated using the Statistical
Package for the Social Sciences (SPSS/Inc, Chicago Ill.
USA) on an Amstrad 1610 personal computer.
RESULTS
All surgeons had experience ofpancreatic resection, but
one had a policy never to perform resection for
adenocarcinoma ofthe pancreas. A total of703 resections
for pancreatic carcinoma was reported by this group of24
surgeons. Median individual experience was 20 resections
(range 0-140).
In their estimate of the cases in which they had left
residual local disease the surgeons reported a median
incidence ofresidual disease of 12.5%. The rangewas from
0-35%, and six (25%) surgeons claimed theyhad never left
macroscopic residual local disease during resection for
pancreatic adenocarcinoma.
The responses to the question of whether palliative
resection is appropriate are shown in Figure 1. The initial
response oftwo thirds ofthe surgeons was that it is never
appropriate to perform palliative resection, but when
asked specifically to consider local extension, the surgeons
were split evenly in their acceptance of the principle of
palliative resection. Only three surgeons felt that it could
ever be justified to perform pancreatic resection in the
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Table Questionnaire sent to British surgeons to determine their
attitudes to palliative resection of pancreatic adenocarcinoma
Do you believe it is ever appropriate to perform a palliative
resection?
Is it appropriate to perform palliative resection with residual
local disease?
Is it appropriate to perform palliative resection in the
presence of liver metastases?
How many resections for pancreatic cancer have you carried out?
On how many occasions was there residual local disease (obvious to
the surgeon at operation)?
How many times have you performed a pancreatic resection in the
presence ofknown liver metastases?
How long have such patients survived?
presence of liver metastases. One ofthese had performed
three or four elective palliative resections with post-
operative survival ranging from six to 18 months. One
surgeon had performed palliative resection in the
presence of liver metastases, in order to control
haemorrhage from a tumour bleeding into the duodenum.
One who approved of palliative resection in some
circumstances had never seen a suitable case.
DISCUSSION
Opinion amongst British surgeons regarding the merit of
palliative resection ofpancreatic adenocarcinoma varies
widely. Some have very strict criteria for resection, and
avoid operation whenever the tumour might have spread
outside the pancreas. Halfthe surgeons in this survey are
prepared to accept residual macroscopic local invasion if
this is discovered during the course of a resection.
Palliative resection in the presence of liver metastases is
approved by only a small minority.
Palliative resection can only be acceptable 1) ifopera-
tive mortality is low, and 2) if resection produces better
palliation than other treatments. The first criterion has
been achieved by most surgeons with an interest in this
condition ,2. The question of quality of palliation relies
entirely on opinion3. There are no satisfactory published
assessments of quality of life achieved by resection or
surgical and other forms of palliation, but a Norwegian
study has recorded objective evidence ofbetter quality of
life in patients who had resection compared to surgical
bypass (Bakkevold, Personal Communication). There is
preliminary evidence of longer survival in patients who
undergo resection compared with patients who have
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similar stage tumourswho did not have a resection4, and it
is reasonable to suppose that tumour debulking might
prolong survival.
Palliative resection leaving residual local disease might
be considered in conjunction with postoperative adjuvant
therapy. Postoperative radiotherapy with 5FU as a
radiosensitiser, followed by weekly 5FU, has been shown
to increase postoperative survival from 20% to40% at two
years5. A similar regimen produced responses in a
significant number ofpatients with irresectable pancreatic
cancer6, so it is reasonable to suppose that palliative
resection followed by adjuvant therapy could give
effective local control in some patients. However there are
no published data to support this supposition.
Pancreatectomy for ductal or adenocarcinoma in the
presence of liver metastases is rarely undertaken. In
addition to the cases mentioned here, Jeekel (Personal
Communication) has performed such a resection in three
patients. One patient is still alive more than two years after
operation. In Mannheim, a small number of combined
pancreatic and liver resections have been performed for
this type ofcase, but the outcome is not clear7.
In conclusion itnow seems that palliative resection is a
feasible option in the management ofpancreatic cancer.
The exact definition of palliative resection is not clear,
because even after so called curative resection the vast
majority of patients die of tumour recurrence. The
majority of British surgeons do not yet accept the concept
ofpalliative resection to improve symptoms. Evidence of
improved quality of life is lacking and studies are urgently
needed to evaluate this in patients undergoing surgical and
other treatments for pancreatic cancer. Resection for
pancreatic carcinoma with liver metastases is accepted
only by a small number ofsurgeons and then only in very
carefully selected patients with minimal tumour burden.
Improvements in adjuvant therapy are required, to match
improvements already seen in operative mortality, before
palliative resection will be widely accepted.
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